These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Whither an anti-hCG approach for the control of fertility.
    Journal: Res Reprod; 1981 Jul; 13(3):1-2. PubMed ID: 12263408.
    Abstract:
    2 groups of investigators reported their strategies for developing an anti-hCG vaccine 5 years ago. 1 group used a C-terminal peptide of beta-hCG and the other group proposed immunochemically purified beta-subunit of hCG linked covalently to a highly purified bacterial vaccine tetanus toxoid to elicit anti-hCG response. hCG was chosen as a target for immunointerception because of its known essential role in maintaining early pregnancy. Since that time, research has furthered knowledge on the immunodominant and immunorecessive parts of the beta-subunit of the hCG. The target tissues seem to react optimally with the associated subunits. beta-hCG produces antibodies which have preferential reactions with hCG but variable crossreactions with hLH. Acute and subacute tocicity studies with the vaccine based on immunochemically purified beta-hCG linked to tetanus toxoid have shown no side effects in the recipients. The tests also showed that these vaccines have the same limitations as vaccines of other types: 1) there is a wide variability of antibody titres among individuals and those with low titres were not protected from pregnancy; and 2) there is individual variability of responsiveness to different antigens. Work on the possibility of passive immunization against h-CG continues.
    [Abstract] [Full Text] [Related] [New Search]